» Articles » PMID: 32585362

Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis

Overview
Specialty Gastroenterology
Date 2020 Jun 26
PMID 32585362
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Acute pouchitis is the most common non-surgical complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). We used validated case-finding definitions for pouchitis to search administrative claims data and determine the incidence of pouchitis in the first 2 years after IPAA.

Methods: We identified all patients who underwent proctocolectomy with IPAA for UC in the IQVIA Legacy PharMetrics Adjudicated Claims Database, from January 1, 2007 through June 1, 2016. The primary outcome was the development of pouchitis within 2 years after IPAA. Secondary outcomes included isolated acute vs recurrent pouchitis, immunosuppressive therapy, further surgery, and admission to the hospital.

Results: Among 594 patients, the cumulative incidence of pouchitis within 2 years of IPAA was 48% (95% CI, 44%-52%). The cumulative incidence of isolated acute pouchitis was 29% (95% CI, 26%-33%). Compared to patients with isolated acute pouchitis, patients who received a diagnosis of recurrent pouchitis (cumulative incidence, 19%: 95% CI, 16%-22%) demonstrated increased outpatient visits, emergency department visits, and inpatient admissions (all P < .001). Patients who developed pouchitis were more likely to have a history of primary sclerosing cholangitis (adjusted odds ratio [aOR], 3.94; 95% CI, 1.05-14.8) and anti-tumor necrosis factor alpha therapy prior to colectomy (aOR 1.63; 95% CI, 1.09-2.45). Among patients with pouchitis, the cumulative frequency of new immunosuppressive therapy was 40% (95% CI, 35%-46%) and the cumulative incidence of pouch excision was 1.0% (95% CI, 0.4%-3.0%). The cumulative incidence of a new diagnosis of Crohn's disease after IPAA for UC was 9.0% (95% CI, 7.2%-11%).

Conclusions: In a geographically diverse population, 48% of patients with UC developed pouchitis within the first 2 years after IPAA. Patients with pouchitis had greater use of healthcare resources, indicating a significant burden of disease.

Citing Articles

Pouch outcomes after minimally invasive vs. open proctectomy during IPAA reconstruction.

Metzger D, Mesiti A, Johnson J, Li Y, Brouwer J, Manasa M Surg Endosc. 2025; .

PMID: 39979620 DOI: 10.1007/s00464-025-11574-y.


Pouchitis unveiled: exploring clinical features, diagnosis, and cutting-edge treatments.

Lusetti F, Martins Helfenberger C, de Mello M, Queiroz N Therap Adv Gastroenterol. 2025; 18:17562848251316412.

PMID: 39877662 PMC: 11773515. DOI: 10.1177/17562848251316412.


Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study.

Honap S, Caron B, Ollech J, Fischman M, Papamichael K, de Jong D Dig Dis Sci. 2025; .

PMID: 39869163 DOI: 10.1007/s10620-024-08821-y.


Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis.

Bernardi F, Fanizzi F, Parigi T, Zilli A, Allocca M, Furfaro F Microorganisms. 2025; 13(1).

PMID: 39858787 PMC: 11768050. DOI: 10.3390/microorganisms13010019.


Effect of Fecal Microbiota Transplant on Antibiotic Resistance Genes Among Patients with Chronic Pouchitis.

Claytor J, Lin D, Magnaye K, Guerrero Y, Langelier C, Lynch S Dig Dis Sci. 2025; .

PMID: 39804518 DOI: 10.1007/s10620-024-08828-5.


References
1.
Long M, Hutfless S, Kappelman M, Khalili H, Kaplan G, Bernstein C . Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis. 2013; 20(2):398-415. PMC: 4610029. DOI: 10.1097/01.MIB.0000435441.30107.8b. View

2.
Barnes E, Kochar B, Herfarth H, Winter R, Long M, Korzenik J . Creation of a Case-Finding Definition for Identifying Patients With Acute Pouchitis in Administrative Claims Data. Clin Gastroenterol Hepatol. 2020; 19(4):842-844.e1. DOI: 10.1016/j.cgh.2020.03.003. View

3.
Segal J, Ding N, Worley G, McLaughlin S, Preston S, Faiz O . Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Aliment Pharmacol Ther. 2016; 45(5):581-592. DOI: 10.1111/apt.13905. View

4.
Madiba T, Bartolo D . Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J R Coll Surg Edinb. 2002; 46(6):334-7. View

5.
Shen B, Fazio V, Remzi F, Brzezinski A, Bennett A, Lopez R . Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2006; 4(1):81-9. DOI: 10.1016/j.cgh.2005.10.004. View